Home
»çÀÌÆ®¸Ê
Contact Us
Eng
¼¾ÅͼҰ³
¿¬±¸¿µ¿ª
¿¬±¸È°µ¿
¿¬±¸½ÇÀû
ÀÚ·á½Ç
°Ô½ÃÆÇ
×
¼¾ÅͼҰ³
Àλ縻
¼³¸³¸ñÀû
¿¬Çõ
Á¶Á÷µµ
Âü¿©¿¬±¸Áø
½Ã¼³ ¹× Àåºñ
¿À½Ã´Â ±æ
¿¬±¸¿µ¿ª
ÀÓ»ó¾à¹°À¯Àüü¿¬±¸ºÎ
ºÐÀھ๰À¯Àüü¿¬±¸ºÎ
¾à¹°À¯Àüü¿¬±¸ Áö¿øºÎ
¿¬±¸È°µ¿
¿¬±¸»ç¾÷
¿¬±¸°³¹ß
¿¬±¸Çù·ÂÁö¿ø
Àη¾缺
¿¬±¸½ÇÀû
ÁßÁ¡¿¬±¸ÀÚ·á
³í¹®½ÇÀû
ÇÐȸ¹ßÇ¥
ƯÇã½ÇÀû
±âŸ½ÇÀû
ÀÚ·á½Ç
º¸µµÀÚ·á
»çÁøÀÚ·á
°ü·Ã»çÀÌÆ®
°Ô½ÃÆÇ
Çà»çÀÏÁ¤
°øÁö»çÇ×
¼¾ÅͼҽÄ
Çаè¼Ò½Ä
Contact Us
Eng
³í¹®½ÇÀû
¿¬±¸½ÇÀû
ÁßÁ¡¿¬±¸ÀÚ·á
³í¹®½ÇÀû
ÇÐȸ¹ßÇ¥
ƯÇã½ÇÀû
±âŸ½ÇÀû
Áö¿ø°úÁ¦º° :
¼±ÅÃÇϱâ
BMRC
BMRC, Japan Fund
BMRC, PRCDM
BMRC, ¼ö¼Ûü
cPMTb
FRONTIER
FRONTIER, PRCDM
NRL
NRL, PRCDM
PRCDM
PRCDM, ¿¬±¸±³¼ö
RCTC
RCTC, BMRC
¿¬µµº° :
¼±ÅÃÇϱâ
2015-International
2015-Domestic
2014-International
2014-Domestic
2013-International
2013-Domestic
2012-International
2012-Domestic
2011-International
2011-Domestic
2010-International
2010-Domestic
2009-International
2009-Domestic
2008-International
2008-Domestic
2007-International
2007-Domestic
2006-International
2006-Domestic
2005-International
2005-Domestic
2004-International
2004-Domestic
2003-International
2003-Domestic
¸ðµÎº¸±â
·
Anh NK, Phat NK, Yen NTH, Jayanti RP, Thu VTA, Park YJ, Cho YS, Shin JG, Kim DH, Oh JY, Long NP
Comprehensive lipid profiles investigation reveals host metabolic and immune alterations during anti-tuberculosis treatment: Implications for therapeutic monitoring(cPMTb)
Biomed Pharmacother. 158:114187 / 2023.02 [
LINK
]
·
Jang YN, Cheong WY, Park GR, Kim YM, Ha JB, Ahn SZ
Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma(cPMTb)
J Pers Med. 13(2):188 / 2023.01 [
LINK
]
·
Anh NK, Tung PM, Kim MJ, Long NP, Cho YS, Kim DH, Shin JG
Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS(cPMTb)
Molecules. 27(23):8607 / 2022.12 [
LINK
]
·
Le TK, Park YJ, Cha GS, Oktavia FARH, Kim DH, Yun CH
Roles of Human Liver Cytochrome P450 Enzymes in Tenatoprazole Metabolism(cPMTb)
Pharmaceutics. 15(1):23 / 2022.12 [
LINK
]
·
Ahn SZ
Building and analyzing machine learning-based warfarin dose prediction models using scikit-learn(cPMTb)
Transl Clin Pharmacol. 30(4):172-181 / 2022.12 [
LINK
]
·
Sidamo T, Rao PS, Aklillu E, Shibeshi W, Park YM, Cho YS, Shin JG, Heysell SK, Mpagama SG, Engidawork E
Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis(cPMTb)
Infect Drug Resist. 28:15:6839-6852 / 2022.11 [
LINK
]
·
Yen NTH, Park SM, Thu VTA, Phat NK, Cho YS, Yoon SJ, Shin JG, Kim DH, Oh JH, Long NP
Genome-wide gene expression analysis reveals molecular insights into the drug-induced toxicity of nephrotoxic agents(cPMTb)
Life Sci. 1:306:120801 / 2022.10 [
LINK
]
·
Howlader S, Kim MJ, Jony MR, Long NP, Cho YS, Kim DH, Shin JG
Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro(cPMTb)
Antimicrob Agents Chemother. 66(10):e0056522 / 2022.10 [
LINK
]
·
Alhawari H, Jarrar Y, Abulebdah D, Abaalkhail SJ, Alkhalili M, Alkhalili S, Alhawari H, Momani M, Obeidat MN, Fram RK, Salahat MA, Lee SJ
Effects of Vitamin D Receptor Genotype on Lipid Profiles and Retinopathy Risk in Type 2 Diabetes Patients: A Pilot Study(cPMTb)
J Pers Med. 12(9):1488 / 2022.09 [
LINK
]
·
Kim HK, Kim M, Marquez JC, Jeong SH, Ko TH, Noh YH, Kha PT, Choi HM, Kim DH, Kim JT, Yang YI, Ko KS, Rhee BD, Shubina LK, Makarieva TN, Yashunsky DY, Gerbst AG, Nifantiev NE, Stonik VA, Han J
Novel GSK-3¥â Inhibitor Neopetroside A Protects Against Murine Myocardial Ischemia/Reperfusion Injury(cPMTb)
JACC Basic Transl Sci. 7(11):1102-1116 / 2022.09 [
LINK
]
1
2
3
4
5
6
7
8
9
10
[Next]
Á¦¸ñ
ÀúÀÚ¸í
Áö¿ø°úÁ¦